EnzBond aims to improve enzyme development in the chemical sector. The company developed a computation-only platform for enzyme development that predicts the activity of the enzyme. Their AI platmform is able to predict enzyme stability based on sequence data.
EnzBond’s program is able to quickly predict the turnover of an enzyme, which is the maximum number of chemical conversions of substrate molecules per second that will be executed by a single catalytic site at a given enzyme concentration. The AI program produces thermal shift data. Their technology allows thousands of potential mutants to be screened in a day in order to find the most active enzymes for the molecule of interest.
EnzBond’s in-silico technology allows a company to analyse potential properties of enzymes to speed up the selection process, compared to using trial and error to find the right enzymes for production. EnzyBond’s technology has applications in pharmaceutical, agricultural, cosmetic and synthetic biology areas. The company can assist companies in applying enzymes to production methods for potentially cleaner processes and possible reduced cost for compounds such as antivirals and antibiotics.
EnzBond is an Oxford spinout developed by students Alina Rakhimova and Robert Simion, who developed the underlying technology and pitched the technology to pharmaceutical partners and investors while they were PhD students. Spinning out the company involved Oxford University Innovation and Oxford Sciences Innovation, the investment company that backed EnzBond with seed financing of £350,000.
Dr Alina Rakhimova
Dr Robert Simion